Cyclerion Therapeutics (CYCN) Liabilities and Shareholders Equity (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Liabilities and Shareholders Equity of $10.0 million for Q4 2025, up 4.28% year-over-year from $9.6 million in Q4 2024, and down 4.13% quarter-over-quarter from $10.4 million in Q3 2025.
Cyclerion Therapeutics (CYCN) Liabilities and Shareholders Equity (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $10.0 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 4.28% year-over-year to $10.0 million; the TTM figure through Dec 2025 stood at $39.6 million (down 0.71% YoY), while the FY2025 annual figure was $10.0 million, up 4.28% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $10.0 million, down from $10.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $100.0 million in Q1 2021, with the low at $8.9 million in Q3 2024.
- The 5-year median for Liabilities and Shareholders Equity is $12.4 million (2023), against an average of $27.9 million.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 75.38% in 2023, then rose 17.05% in 2025.
- Cyclerion Therapeutics' Liabilities and Shareholders Equity stood at $59.3 million in 2021, then sank by 69.53% to $18.1 million in 2022, then declined by 26.02% to $13.4 million in 2023, then retreated by 28.41% to $9.6 million in 2024, then advanced by 4.28% to $10.0 million in 2025.
- Business Quant data shows CYCN's Liabilities and Shareholders Equity at $10.0 million in Q4 2025, $10.4 million in Q3 2025, and $9.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | 9.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.99 Mn |
| Sep 30, 2025 | 10.42 Mn |
| Jun 30, 2025 | 9.37 Mn |
| Mar 31, 2025 | 9.85 Mn |
| Dec 31, 2024 | 9.58 Mn |
| Sep 30, 2024 | 8.90 Mn |
| Jun 30, 2024 | 10.07 Mn |
| Mar 31, 2024 | 11.36 Mn |
| Dec 31, 2023 | 13.37 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | 10.10 Mn |
| Mar 31, 2023 | 11.46 Mn |
| Dec 31, 2022 | 18.08 Mn |
| Sep 30, 2022 | 25.05 Mn |
| Jun 30, 2022 | 35.21 Mn |
| Mar 31, 2022 | 46.53 Mn |
| Dec 31, 2021 | 59.33 Mn |
| Sep 30, 2021 | 67.74 Mn |
| Jun 30, 2021 | 75.73 Mn |
| Mar 31, 2021 | 99.97 Mn |